0.25
0.5
0.75
1.25
1.5
1.75
2
Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: Results from a randomized controlled phase 3 trial
Published on Jul 21, 20173058 Views
Objective: Evaluate masitinib plus riluzole (100 mg/kg) in amyotrophic lateral sclerosis (ALS). Background: Masitinib, an oral tyrosine kinase inhibitor targeting CSF1R, generates neuroprotective e
Related categories
Chapter list
Masitinib as an add-on therapy to riluzole is safe and effective in the treatment of ALS00:00
Authors00:08
Rationale for use of masitinib in ALS - 100:34
Rationale for use of masitinib in ALS - 200:38
Rationale for use of masitinib in ALS - 302:23
Rationale for use of masitinib in ALS - 403:36
Rationale for use of masitinib in ALS - 505:54
Rationale for use of masitinib in ALS - 606:47
Rationale for use of masitinib in ALS - 707:54
Overview of trial AB10015 results08:47
Study AB10015 rationale09:29
Study design - 109:52
Study AB10015 design10:04
Study design - 211:44
Study design - 312:32
Study design - 413:30
Study design - 515:32
Study design - 615:57
Study design - 716:29
Study design - 817:48
Baseline characteristics and disposition of patients18:40
Baseline characteristics - 118:45
Summary of the study populatrtion20:03
Baseline characteristics - 220:31
Study results20:49
Step 1 - Masitinib 4.5 mg / Normal progressors20:53
Primary analysis - 121:03
Primary analysis - 221:46
Primary analysis - 322:05
Primary analysis - 422:58
Post hoc analysis23:35
Secondary analyses - 125:13
Secondary analyses - 225:54
Secondary analyses - 326:29
Supportive analyses26:52
Step 2 - Masitinib 3.0 mg / Normal progressors27:23
Primary analysis27:34
Secondary analyses - 128:03
Secondary analyses - 228:32
Untitled28:46
Primary analysis28:57
Post hoc29:16
Safety - 130:07
Safety - 230:10
Safety - 331:36
Summary32:07
Summary study AB1001532:09
Questions34:15